drugset
drugset / Trial / NCT03795922

MT10109L in the Treatment of Glabellar Lines

NCT03795922 ↗

Phase 3 Completed 234 enrolled Medy-Tox
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and efficacy of MT10109L in the treatment of glabellar lines (GL) in participants with moderate to severe GL.

Timeline

Start
2018-12-24
Primary completion
2020-03-13
Completion
2021-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject NivobotulinumtoxinA Protein / enzyme biologic — Other

Indications

No indication recorded.